论文部分内容阅读
Background: Transarterial chemoembolisation(TACE)is still widely used to treat patients with advanced hepatocellular carcinoma who have no access to sorafenib in Asia.However,the indication of TACE for these patients has yet to be established.We established an objective point score to guide this decision in patients with advanced-stage hepatocellular carcinoma.